Oligometastatic Prostate Cancer: How Far Do We Go?
There have been many advancements in terms of treatment and imaging modalities for patients with oligometastatic prostate cancer. Failure to understand these advancements in treatment options leads to lower quality of care delivered by clinicians treating prostate cancer patients.
Category
  • Genitourinary
  • Oligometastatic
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
Stereotactic Radiotherapy and Renal Cell Cancer: Overcoming Radioresistance and the Resistance to Radiate
The use of SABR is well established in many cancers, however, its application within kidney cancer is relatively new. This is largely due to the historical notion that renal cell carcinoma (RCC) is highly radioresistant.
Category
  • Genitourinary
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
Advancement in Imaging for Radiation Oncology
Various advances in imaging are changing the clinical practice for Radiation Oncology.
Category
  • General RO
  • Genitourinary
  • Physics
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
Considerations for Treatment of PSMA-Staged High-Risk Patients in Community Practice
This activity discusses the use of PSMA PET for staging in high-risk prostate cancer. This includes when to order a PSMA PET, how to interpret it, common pitfalls and controversies of the scans.
Category
  • Genitourinary
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
Combined Modality Therapy for Lymph Node Positive Prostate Cancer
Historically, the management of lymph node positive prostate cancer was limited to androgen deprivation therapy, but increasing data now support the use of multimodality therapy. As treatment options have expanded, patient-centered decision making has become increasingly complicated.
Category
  • Genitourinary
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
Management of Unfavorable Intermediate-Risk Prostate Cancer: Role of SBRT, Brachytherapy and Androgen Deprivation
Unfavorable intermediate-risk prostate cancer is commonly encountered in clinical practice but there is relatively little data focusing on treatment outcomes specific and limited to this patient cohort, with most clinical trials grouping these patients with favorable intermediate-risk disease or
Category
  • Brachytherapy
  • Genitourinary
  • SBRT
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
Management of Small Cell Neuroendocrine Tumors of the Genitourinary Tract
Molecular diagnostics are rapidly evolving, leading to increased identification of previously 'rare' clinical entities.
Category
  • Genitourinary
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
Implementation of a Prostate SBRT Program in the Community Setting
Conventionally fractionated external beam radiation therapy (EBRT) has a long-standing track record of safety and excellent treatment outcomes in the management of all prostate cancer risk groups.
Category
  • Genitourinary
  • SBRT
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
“Let’s Talk About It!” - Biology and Management of Sexual Toxicity Resulting from Prostate Cancer Radiotherapy
Radiation therapy-induced erectile dysfunction (RI-ED) occurs in over 50% of men treated for prostate cancer. The etiologies are likely multifactorial, consisting of a neurological, vascular and endocrine component.
Category
  • Genitourinary
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
Sexuality After Cancer Therapy
Patient fertility and sexual complications have few data available from clinical trials. It is noteworthy that the subject is infrequently discussed in institutional peer reviews/ M&M unless there is a Risk Management overlay.
Category
  • Breast
  • Genitourinary
  • Gynecologic
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00